Skip to main content
Clinical Trials/NCT01534936
NCT01534936
Completed
Not Applicable

Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary.

AstraZeneca1 site in 1 country2,153 target enrollmentFebruary 2012

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
AstraZeneca
Enrollment
2153
Locations
1
Primary Endpoint
Change from baseline on clinical global impression scale up to 6 months of schizophrenic outpatients with affective symptoms.
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.

Detailed Description

Atypical antipsychotics in the treatment of affective symptoms of schizophrenia in Hungary

Registry
clinicaltrials.gov
Start Date
February 2012
End Date
December 2012
Last Updated
13 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Schizophrenic outpatients diagnosis based on DSM -IV above 18 years of age with affective symptoms.
  • Atypical antipsychotic treatment at least for a month before study inclusion.

Exclusion Criteria

  • Pregnancy.
  • Hepatic disease.
  • Diabetes mellitus.
  • Severe cerebro- or cardiovascular disease.

Outcomes

Primary Outcomes

Change from baseline on clinical global impression scale up to 6 months of schizophrenic outpatients with affective symptoms.

Time Frame: 3 and 6 months

The Clinical Global Impression Scale (CGI) is a brief clinician-rated instrument. The CGI severity of illness measure (CGI-S) is rated from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). The CGI global improvement measure (CGI-I) is rated from 1 (very much improved) to 7 (very much worse). "0" stands for "not assessed". Means and standard deviations (SD) for CGI-S(baseline), CGI-S (1.visit) CGI-S (2.visit) and for CGI-I will be calculated.

Secondary Outcomes

  • Description of the relation between and the change of affective symptoms and overall clinical status.(3 and 6 months)
  • Assessment of the efficacy of different atypical antipsychotics in the treatment of schizophrenia with affective symptoms measured by the difference in Raskin Scale.(From baseline up to 6 months)
  • Assessment of the efficacy of different atypical antipsychotics in the treatment of schizophrenia with affective symptoms measured by the difference in CGI-S (CGI severity of illness measure) and CGI-I (CGI global improvement measure).(From baseline up to 6 months)

Study Sites (1)

Loading locations...

Similar Trials